Navigation Links
Diasome Pharmaceuticals, Inc. Announces Notice of Allowance from US PTO for Liver Targeting System for Insulin
Date:3/31/2015

Cleveland, OH (PRWEB) March 31, 2015

Diasome Pharmaceuticals, Inc. (http://www.diasome.com) has received notice from its licensor, SDG, Inc., that a United States patent has recently been allowed for the Company’s technology for liver-targeted insulin therapy.

Entitled “Lipid Construct for Delivery of Insulin to a Mammal,” this patent covers composition of matter claims related to the use of Diasome’s proprietary Hepatocyte Directed Vesicles (“HDV”) as a system for enabling injected insulin to more effectively reach the liver’s metabolic cells, called hepatocytes.

“While all naturally secreted insulin is first and primarily used by the liver as a signal to store sugar from the food we eat, injected insulin therapy has been shown to have great difficulty in successfully reaching the liver in patients with diabetes,” said W. Blair Geho, MD, PhD, Diasome’s Chief Scientific Officer. “The HDV system has been designed as a potentially first-in-class additive to approved insulin therapies and has been shown in Phase 2 human testing to have a significant and positive impact on controlling blood sugar levels in patients.”

Diasome’s most advanced clinical-stage therapy is an injected form of pre-meal insulin that incorporates the HDV nanotechnology system. This product has been enabled for Phase 3 testing by the US FDA.

About Diasome Pharmaceuticals, Inc.

Diasome Pharmaceuticals, Inc. is focused on the clinical and commercial development of breakthrough therapies for diabetes and obesity. Based on more than thirty years of research and development in the fields of cell receptor targeting, insulin replacement, and hepatic (liver) glucose metabolism, the Company’s pipeline includes multiple injected and oral formulations of liver targeted insulins for both Type 1 and Type 2 diabetic patients that are Phase 3 ready. In addition, Diasome is developing a first-in-class oral compound for the Type 2 diabetes population that is based upon new insights into normal glucose metabolism and a novel mechanism of action, along with a nanotechnology-based oral compound that may have a significant impact in treating obesity.

Read the full story at http://www.prweb.com/releases/2015/03/prweb12613561.htm.


'/>"/>
Source: PRWeb
Copyright©2015 Vocus, Inc.
All rights reserved

Related biology technology :

1. Diasome Pharmaceuticals, Inc. Announces Issuance of Oral Insulin Patent by the US PTO
2. Auxilium Pharmaceuticals, Inc. To Present At The Goldman Sachs 34th Annual Global Healthcare Conference
3. Life Cycle Management of Biopharmaceuticals, New Life Science Webinar Hosted by Xtalks
4. OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2013 and Addresses Key Questions from Investors on Quarterly Conference Call
5. Biotech Briefing: Advancing Biotechs Forging Ahead With Breaking News Developments: Alliqua, OncoMed Pharmaceuticals, EnteroMedics, Unilife, Amarin
6. Collaborations, FDA Approvals, Appointments, Patents, and Stock Movements - Research Report on Aetna, United Therapeutics, Perrigo, Arena Pharmaceuticals, and Keryx Biopharmaceuticals
7. Open Label Data on Enhanced Sleep Released by JayMac Pharmaceuticals, LLC
8. Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody
9. PlasmaTech Biopharmaceuticals, Inc. Announces Reverse Stock Split, Ticker Change and Launches New Corporate Website
10. Synthetic Biology Market by Tool, Technology (Bioinformatics, Nanotechnology, Gene Synthesis, Cloning & Sequencing), Application (Biofuels, Pharmaceuticals, Biomaterials, Bioremediation) - Global Forecast to 2018
11. PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2019)... ... May 30, 2019 , ... World Compliance Seminars today announced ... 2019 in Boston, MA. This peer recommended interactive workshop is always selected by ... will kick off with a compendial treatment of Data Integrity fundamentals. After laying ...
(Date:5/15/2019)... ... 15, 2019 , ... Milton Hershey School® has named William Charles Ballough Harding ... biomedical industry, where he is changing lives by creating solutions to global healthcare challenges ... the vision of our founders – Milton and Catherine Hershey – who always hoped ...
(Date:5/7/2019)... ... May 06, 2019 , ... "The ... growing number of repositories being asked to store cellular products being used ... of contributors who are world leaders, who have shared their expertise in building ...
(Date:5/2/2019)... ... May 02, 2019 , ... Stay on top of current ... and food industries. Access to all webinars is free, so be sure to register ... field! , Visit http://www.xtalks.com to see our upcoming webinars: , CLINICAL TRIALS ...
Breaking Biology Technology:
(Date:6/19/2019)... ... ... Dahryn Trivedi, today released research results on the beneficial impact of biofield ... be beneficial for treating multiple bacterial diseases. , The preclinical trial shows:, ... decrease in weight , Over 8% alteration in melting point ...
(Date:6/13/2019)... ... June 13, 2019 , ... KICVentures announced today its plans ... Orthopedic and Pain Management-Driven ASC Conference in Chicago on Thursday, June 13th at 6:30 ... Dr. Chicago, IL in the 3rd floor Ticino Hospitality room in space #74T. , ...
(Date:6/6/2019)... ... June 05, 2019 , ... Pelican BioThermal , ... station and service center in Mexico City, Mexico. Mexico is the second largest ... more than $1.75 billion in pharmaceutical exports since 2015. The Mexico City network ...
Breaking Biology News(10 mins):